LAWRENCEVILLE, N.J., Oct. 12, 2015 /PRNewswire/ — Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today reported data from a large preclinical study of the Company’s GEN-1 IL-12 immunotherapy in combination with Avastin® and Doxil® for the treatment of ovarian cancer. Results from the comprehensive studies confirmed remarkable initial GEN-1 + Avastin findings and show convincingly that GEN-1 when combined with Avastin® and Doxil®, standard of care for platinum resistant patients, demonstrated a greater than 98% reduction in tumor burden when compared to the untreated control group. The findings represent a statistically significant reduction in tumor burden and disease progression when compared to the combination of Avastin® and Doxil® in a SKOV3 human cell line implanted into immunocompromised (nude) mice.read more
Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease
INDIANAPOLIS, Oct. 12, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and the ACCELERATE study’s academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy. Lilly will discontinue development of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease and will now conclude other studies in the program. read more
New Data Show Consistent Safety Profile For Up To 10 Years With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis
THOUSAND OAKS, Calif., Oct. 12, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced results from a seven-year, single-arm, open-label extension of the three-year randomized, double-blind, placebo-controlled, multicenter, international Phase 3 Fracture Reduction Evaluation of Denosumab in Osteoporosis every six Months (FREEDOM) study. In this final analysis, treatment with Prolia® (denosumab) for up to 10 years showed that the overall incidence of adverse events (AEs) and serious AEs remained consistent over the duration of the study with a low fracture incidence. In addition, postmenopausal women with osteoporosis on Prolia continued to show gains in bone mineral density (BMD) over 10 years. The findings were presented during a late-breaking oral presentation session at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting in Seattle today. read more
Medtronic CoreValve® System Demonstrates Excellent Clinical Outcomes in First Report of ‘Real-World’ U.S. Experience
DUBLIN and SAN FRANCISCO – October 12, 2015 – Medtronic plc (NYSE: MDT) today released the first CoreValve® Transcatheter Aortic Valve Replacement (TAVR) System outcomes data using CoreValve data from The Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry. The data show that everyday clinical experience from read more
Savolitinib Completes Enrolment for Phase II Clinical Trial in Papillary Renal Cell Carcinoma
Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) have completed enrolment in a global Phase II study of savolitinib (AZD6094), a potent and highly selective mesenchymal epithelial transition factor (“c-Met”) inhibitor. This is a Phase II study to evaluate the efficacy and safety of savolitinib monotherapy (600 mg once daily) in papillary renal cell carcinoma (“PRCC”) in the United States, Canada and Europe. PRCC represents about 14% of all new cases of kidney cancer.
Rebiotix Receives Breakthrough Therapy Designation for RBX2660 — A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection
ROSEVILLE, Minn., Oct. 12, 2015 /PRNewswire/ — Rebiotix Inc. today announced that U.S. Food and Drug Administration (FDA) has designated its lead Microbiota Restoration Therapy (MRT) RBX2660 as a Breakthrough Therapy for the treatment of recurrent Clostridium difficile (C diff) infection, a challenging to treat gastrointestinal (GI) infection that causes 29,000 deaths in the U.S. annually.1 Rebiotix is a clinical stage biotechnology company that was founded to revolutionize the treatment of debilitating GI diseases by harnessing the power of the human microbiome. MRT is the Rebiotix drug platform for delivering healthy, live, human-derived microbes into a sick patient’s intestinal tract to treat disease. read more
The Economist Events’ War on Cancer 2015
The Economist Event’s inaugural War on Cancer 2015 will bring together the leaders in oncology from across the field and around Europe to explore and shape the dialogue on cancer. With a focus on cross-sector collaboration to improve the health and wealth of Europe’s nations and people, the programme will take a multi-faceted approach. It will examine leading initiatives in policy and financing, innovation in prevention, treatment and diagnosis and new methods of community engagement.
Fostering dialogue on the human and economic cost of cancer, European policy and financing solutions and the importance of innovation across the treatment pathway . Tweet your questions ahead of the event via @EconomistEvents #EconWaronCancer
Daiichi Sankyo Partners With World Thrombosis Day to Promote Awareness of Venous Thromboembolism and Atrial Fibrillation, Helping to Reduce Preventable Deaths